FUTURE OF HEALTHCARE

Tebra CTO Kyle Ryan Named to the Healthcare Technology Report’s List of Top Healthcare Technology CTOs of 2022

Tebra | November 22, 2022 | Read time : 01:00 min

Tebra CTO

Tebra, a leader in practice growth technology and cloud-based clinical and financial software, announced that its Chief Technology Officer Kyle Ryan was named in the Healthcare Technology Report’s list of Top 25 Healthcare Technology CTOs of 2022. The annual list recognizes the most accomplished executives in healthcare technology who are leading teams in delivering cutting edge products that boost operations and improve efficiency for their customers.

The CTOs on this year’s list have a wide range of impressive backgrounds, but each is the driving force behind their company’s technology innovations, ensuring software functionality and effectiveness. Read the full report here.

Kyle has been an integral part of the executive leadership team at Tebra and has built a strong partnership between product management and the technology team within the organization. He has vast knowledge about healthcare IT and how it applies to solving business problems and is keenly customer focused and is always taking time to understand customer needs at a deeper level. Kyle’s an outstanding ambassador for the company and prides himself on developing a healthy and high-performance culture.”

Dan Rodrigues, CEO of Tebra

Kyle is responsible for all areas of technology with a focus on the vision and strategy for Tebra’s suite of products and services. He believes that great products are created through a keen customer focus, groundbreaking ideas, precise engineering, and efficient execution.

“I am honored to be included in this list of prestigious technology leaders,” Kyle said. “This recognition also highlights the technology team’s passion for improving healthcare and the company’s mission of providing independent practices with digital tools and support to thrive in a new era of healthcare.”

About Tebra
In 2021, with a combined mission to unlock better healthcare, Kareo and PatientPop joined forces to form Tebra — the operating system for the connected practice of the future. With an all-in-one, purpose-built platform to drive practice success and modernize every step of the patient journey, Tebra provides digital tools and support to attract new patients, deliver modern care, get paid quickly, and operate efficiently. 

Spotlight

Reducing the cost of medical care, rather than health insurance, is so often underemphasized or even absent from discussions of reforming the health care system. And yet lowering costs of medical care is essential for broadening access to care, reducing insurance premiums and ultimately ensuring better health.


Other News
HEALTH TECHNOLOGY,MEDICAL DEVICES

Predictive Health Solutions Technology Shows Promise in Combating Patient Appointment No-Shows

Predictive Health Solutions | December 06, 2022

With the Predictive Health Solutions Patient No-Show Predictor, providers now have a new tool in combatting patient no-shows. By leveraging the power of predictive analytics, the PHS Patient No-Show Predictor can also help reduce patient backlogs and long waitlists, improve operational efficiencies, promote better patient health outcomes, increase potential revenues, enhance patient care, and minimize caregiver burnout. Powered by SAS analytics software and co-developed by Pinnacle Solutions, the solution seamlessly integrates cutting edge technology into pre-existing daily operations, making it easy for healthcare staff to use. The solution identifies high-risk patients as well as potential key risk factors impacting a patient's ability to attend their appointment, such as weather, social determinants of health, or many other factors. Using the information provided, staff can quickly make informed decisions regarding intervention strategies that directly impact the patient's likelihood of attending their appointment and receiving the care they need. For example, staff may choose to offer alternative options to those with unreliable transportation or suggest afternoon appointments for those whose morning commute would be impacted by traffic delays. Teams may also choose to use the intelligence gathered to customize individual reminder protocols to maximize the impact and value of those existing tools. Data gathered can also be leveraged for strategic overbooking, as opposed to, for example, blindly scheduling same-day appointments. Patient no-shows cost the US and Canadian healthcare systems more than $150 billion annually, and those numbers are likely higher as a result of the COVID-19 pandemic. The ensuing funding shortages not only impact the bottom line, but also directly affect healthcare systems' ability to provide the desired level of care, which in many cases creating even greater accessibility and availability issues. For instance, revenue lost as a result of no-shows could be used to fund additional medical staff or provide the latest medical technologies and therapy sessions for patients in need. Predictive Health Solutions is a joint venture with Pinnacle Solutions, Inc. and the Center For Discovery, Innovation and Development an affiliate member of RWJBarnabas Health and a member of Children's Miracle Network Hospitals. PHS was established to improve access to healthcare, improve diagnostic algorithms, and enhance patient outcomes. PHS uses patient data and external sources to develop solutions that address healthcare needs better. Using machine learning algorithms and artificial intelligence, PHS helps organizations create optimal health for their communities.

Read More

DIGITAL HEALTHCARE, MEDICAL DEVICES

Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products

Sharps Technology Inc | December 21, 2022

Sharps Technology, Inc. an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary. The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply. Sharps innovative syringe designs provide a beneficial set of features and advantages for the healthcare industry. These syringe product features include a combination of ultra-low waste, passive and active safety, and reuse prevention. By combining all these features and building them into a portfolio of syringe offerings, it will create product platforms that can help drive down the cost of healthcare treatments. “This is a transformative point for our company as we move from a pre-revenue research & development start-up to a true manufacturing company that should generate revenue in the first half of 2023. Today’s healthcare providers are responsible for managing their supply chains and driving down their total cost of ownership (TCO) for medical treatments. Sharps Technology will be able to offer products that can directly support those programs. At Sharps Technology, we feel that by using better drug delivery technology, we can help create additional medical treatments at no additional cost for patients that need them." Robert Hayes, Sharps Technology CEO "We look forward to a bright future at Sharps Technology," concluded Mr. Hayes. "The recently signed distribution agreement with Nephron Pharmaceuticals accelerates the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary. The ability to pull forward our sales plan for customers in the US will create a unique opportunity for early revenue at Sharps. We expect to have our first products available for sale in the US by the end of January 2023, with additional products to be added to the distribution network by mid-year of 2023." When healthcare providers use ultra-low waste syringes with multi-dose vials, it allows for the availability of up to 20% to 40% more medication for patients that need the treatment. This medication availability is created by using more efficient syringes designated as low-waste and ultra-low waste products, and not trapping medication within the syringe after the dose is given. The use of standard syringes that are not designated as low waste or ultra-low waste products typically creates a dead space area within the syringe where excess medication is trapped and cannot be used. This dead space then causes the healthcare provider to throw away the unused medication. The trapped medication in the dead space of a standard syringe can waste as much as 100 microliters of medication or more. The Pharmaceutical companies that fill their medication into vials understand this and must then overfill the vial with drug therapy to compensate for the problem. As the costs for medication and medical treatments rise, the discarded medication can cost the industry millions of dollars, or more, globally. The purchase of the European facility was finalized in the summer of 2022 and Sharps has invested in infrastructure and equipment upgrades to prepare the plant for a full manufacturing schedule. Syringe products produced by Sharps comply with all applicable FDA and ISO requirements and have been awarded the European Union’s CE Mark. The Sharps Hungary team, led by General Manager Filippo Filippi, brings together a dedicated and knowledgeable manufacturing force, with more than 20 years of experience in supplying the world with high quality, innovative syringe products. Prior to the GM position, Filippi’s career spanned years of building, managing, and supporting multiple manufacturing sites across Europe, Asia, and Africa. The Hungary plant is vertically integrated in that it has the capability to manufacture the syringe components by injection molding, assemble the devices on automated lines or by manual assembly if required, and to sterilize the products on-site through the Ethylene Oxide sterilization process. This last stage of the syringe manufacturing process is unique in the industry and gives Sharps an advantage in supporting shortened lead times as compared to the common need to utilize a third-party for sterilization. The plant has manufacturing capacity to supply more than 50 million units today and the facility could be expanded to produce 250 million units or more over the next couple of years. About Sharps Technology Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US..

Read More

FUTURE OF HEALTHCARE

Radius XR™ Named as the CES 2023 Innovation Award Honoree for Wearable Device That Combines Therapy and Diagnostic Capabilities

Radius XR | November 17, 2022

Today at the CES Unveiled New York event, Radius XR™, a new fashion-forward wearable healthcare technology brand, was named a CES® 2023 Innovation Awards Honoree in both the Digital Health and Virtual & Augmented Reality categories. Radius was selected from among a record number of submissions to this year’s CES Innovation Awards program. The announcement was made ahead of CES 2023, the influential technology event, happening Jan. 5-8 in Las Vegas, NV. Radius XR builds on the therapeutic legacy of IrisVision, a leader in digital vision technologies and itself a 2019 CES Innovation Winner. The Radius proprietary XR assistive device brings together—for the first time—multimodal diagnostics, practice management, and patient engagement. “This is a tremendous honor for our new company. It follows on the success of our IrisVision visual assistive device, which has provided a life-changing solution for thousands of individuals living with legal blindness and low-vision conditions. Radius expands on our commitment to vision health by providing the eyecare industry with an easy-to-use wearable device capable of performing standard perimetry tests. Other exams include color vision, visual acuity, contrast sensitivity—a comprehensive suite of standard vision tests. Development of additional exams is ongoing.” Radius founder and CEO Ammad Khan Radius enables patients to quickly and easily conduct vision tests with minimal guidance or intervention by the staff. The device’s RadiusExam® software and proprietary algorithms provide diagnostic testing results equivalent to current exam gold standards. “By designing our own hardware and software, we’re able to overcome many of the challenges inherent in the off-the-shelf headsets already on the market. Matching visual field strategies, background luminance, stimulus size and dynamic range allows us to mirror the current standards, making it easy and intuitive for clinicians to transition to Radius,” said John Trefethen, Radius Chief Marketing Officer. In addition, the included Business Suite helps clinicians manage everyday aspects critical to their practice's ongoing success. Features like patient education, staff training and clinician onboarding are now possible inline with the Radius platform. Radius is the industry’s lightest wearable device and has the look and feel of a pair of stylish sunglasses. The compact, lightweight design overcomes the challenges of expensive and bulky legacy devices that force patients to sit in uncomfortable positions for testing. With Radius, exams can be conducted anywhere, even in the waiting room, eliminating the need to shuttle patients between machines, which can be challenging for individuals with mobility or vision issues. The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)®, is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetics, and design. The CES 2023 Innovation Awards honorees, including product descriptions and photos, can be found at CES.tech/innovation. Radius will be on display at the Innovation Awards Showcase at CES 2023 in Las Vegas in January. About Radius XR The Radius XR platform is a portable vision diagnostic and patient engagement system that combines medical-grade diagnostics, business management, and patient education tools in a single wearable XR device. The RadiusExam® and proprietary algorithms provide diagnostic testing results equivalent to current exam gold standards, with the clinical science validated by Deming regression. As the algorithm presents stimuli to patients, it adapts to responses to maximize the algorithm's speed. The total hardware and software system helps medical professionals diagnose patients with accuracy, grow their eyecare practices, enhance patient engagement, and reduce staff workload by enabling patients to perform self-guided vision exams with minimal supervision.

Read More

FUTURE OF HEALTHCARE, HEALTHCARE ANALYTICS

Juno Medical Raises $12M Series A Led by NEXT VENTURES and Serena Ventures; Funding Will Fuel Juno's National Expansion

Juno Medical | December 12, 2022

Juno Medical, the modern doctor's office that's designed for the 99%, today announced $12 million in Series A funding co-led by Julian Eison, Managing Partner at NEXT VENTURES, and Serena Williams, Managing Partner at Serena Ventures. Juno’s comprehensive tech-enabled healthcare model is designed to meet the everyday healthcare needs of "the 99%,” with a specific focus on revitalizing neighborhoods across the United States and delivering a beautiful environment, transparent pricing, and exceptional care. The funding will support Juno’s continued development of its technology platform and expansion into new markets, including Atlanta, Georgia, Tulsa, Oklahoma, and Los Angeles, California. Other notable participants include Vast Ventures, which led Juno’s seed round, Empire State Development’s New York Ventures, TXV Partners, Genius Guild, Gaingels, and previous investors Atento Capital and Humbition. Juno’s team has unmatched healthcare, technology, and business expertise. Juno Founder and CEO Dr. Akili Hinson’s background spans medicine and business. He is a physician by training and former McKinsey & Company consultant with expertise in payment innovation, value-based care delivery, and digital transformation. Juno’s medical leadership team includes Chief Health Officer Dr. Aarti Agarwal, an internist and epidemiologist with expertise in global health and value-based care, as well as Juno’s two founding physicians, Dr. Shante Hinson, a rheumatologist and preventative health expert dedicated to bridging the healthcare gap in underserved communities, and Dr. Candice Fraser, an OB/GYN with over a decade of experience as a trusted guide in women's health. “Juno’s vision is to reimagine the future of healthcare by finally making exceptional, family-centered care accessible and affordable for the 99% all across the United States. At Juno, we’ve designed healthcare that people love by providing the highest quality care and incredible service in a beautiful environment that feels like a place to belong—all powered by modern technology. We are honored by the support of the thousands of patients who have trusted us with their care and our investors who believe in us — we could not be more excited to bring Juno to more neighborhoods and communities all across the country.” Dr. Akili Hinson Juno’s products and services are designed for the family’s “Chief Caregiver” by bringing the best of primary care, pediatrics, women's health, same-day care, and virtual care into one thoughtfully designed experience. “It brings joy to my heart knowing Juno is on a mission to bring exceptional healthcare to cities and developing areas of our nation where suboptimal care, facilities, and services have been tolerated out of necessity for way too long," said Julian Eison, Managing Partner of NEXT VENTURES. “I believe Juno’s hybrid approach leveraging brick and mortar clinics paired with digital access is an enduring model that will serve as the fundamental basis to build community trust and outcomes to match. It’s an honor to have partnered with such an esteemed team, attacking one of the largest problems of our time.” Juno accelerated the opening of its first location in the Harlem neighborhood of New York City to see patients in April 2020 when the COVID-19 pandemic devastated New York and many physician offices were closed. In addition to providing COVID testing and care to hundreds of residents, Juno continued to offer in-person preventive care during the pandemic which led to the identification of treatable cancers and previously undiagnosed chronic conditions in asymptomatic women and men — which may have been missed in the absence of the founding team’s commitment to serve. “We are honored to partner with Juno to expand upon their inclusive, full-service healthcare home model where people from all backgrounds feel seen, heard and welcome,” said Serena Williams, Managing Partner of Serena Ventures. “There is a serious need to address equity issues in healthcare, mental health and wellness services that many communities face. Juno and its talented team have the vision, model and track record to disrupt the unacceptable status quo in healthcare.” Juno’s approach and presence in underserved communities is part of the solution to a growing challenge of healthcare disparities that exist across the United States. A recent report from the Kaiser Family Foundation outlined race-based disparities in maternal and infant health and mortality. The markets in which Juno will expand have their own unique health care challenges. On November 1, Atlanta Medical Center closed its doors, leaving an already-strained healthcare system with one less option and exacerbating concerns about the future of safety net hospitals in the region and state. In North Tulsa, where Juno’s clinic will be located, residents have a life expectancy 13 years shorter than their neighbors in South Tulsa. “Empire State Development’s New York Ventures exists to partner with promising startups that are working to solve the world’s most important challenges, and we are proud to support Juno Medical as they strive to provide exceptional healthcare to New Yorkers, especially in areas that are often overlooked or left behind,” said Hope Knight, President, CEO and Commissioner of Empire State Development. “Juno’s success in New York State is a road map for the future and a proven model for delivering quality, affordable healthcare for all.” Unlike recent trends in concierge medicine and digital health, Juno’s model is designed to work with nearly all types of insurance—including commercial plans, Medicare and Medicaid—without initial barriers or exclusive membership fees. Juno is taking a different approach to meet the needs of busy households by offering additional plans that start at $20 per month per person or $50 per month per family that complement its core services with added conveniences like night and weekend appointments, savings, and unique events and experiences. Juno’s hybrid model includes both in-person options for patients and a robust e-health platform, which includes an app that allows patients to make appointments, manage care information, and keep in touch with their care team. As part of its mission to create a healthier world, Juno will use this funding to expand into new markets and recruit the highest-caliber provider talent in Atlanta, Tulsa and Los Angeles. Juno’s new clinics will be located in the historic yet overlooked neighborhoods of East Atlanta, Greenwood (Tulsa), and Inglewood (Los Angeles). The funding will also support the continued expansion of Juno’s robust technology platform for both patients and healthcare providers—a critical component of Juno’s innovative model. About Juno Medical Launched in April 2020, Juno Medical is a tech-enabled healthcare service provider designed for you and yours. The company offers exceptional hospitality, modern technology, and transparent prices that won't break the bank and brings the best of adult primary care, pediatrics, women's health, and same-day care into one thoughtful and beautifully designed place.

Read More

Spotlight

Reducing the cost of medical care, rather than health insurance, is so often underemphasized or even absent from discussions of reforming the health care system. And yet lowering costs of medical care is essential for broadening access to care, reducing insurance premiums and ultimately ensuring better health.

Resources